Comparative evaluation of single and bilayered lamotrigine floating tablets

PK Lakshmi, M Sridhar, B Shruthi
Department of Pharmaceutics, G Pulla Reddy College of Pharmacy, Mehdipatnam, Hyderabad, Andhra Pradesh, India

Abstract

Aim: The purpose of this study was to prepare lamotrigine (LM) bilayered and single layered floating tablets and to compare their release profiles. Materials and Methods: LM floating tablets were prepared by direct compression method. Drug, hydroxy propyl methyl cellulose K4M, lactose monohydrate and polyvinylpyrrolidone K30 constitute controlled release layer components and floating layer components includes polymers and sodium bicarbonate. The prepared tablets were evaluated for physicochemical parameters such as hardness, friability, weight variation, thickness, floating lag time (FLT), floating time, in vitro buoyancy study, in vitro release studies. The drug-polymer interaction was studied by fourier transform infrared and differential scanning calorimetry. Results and Discussion: The FLT of all the formulations were within the prescribed limits (<3 min). When ethyl cellulose was used as floating layer component, tablets showed good buoyancy effect but eroded within 6-8 h. Hence it was replaced with hydroxypropyl cellulose -M hydrophilic polymer, which showed good FLT and floating duration for 16 h. Formulation LFC4 was found to be optimized with dissolution profile of zero order kinetics and showing fickian diffusion. A comparative study of bilayered and single layered tablets of LM showed a highest similarity factor of 83.03, difference factor of 2.74 and t-test (P < 0.05) indicates that there is no significant difference between them. Conclusion: Though bilayered tablet possess many advantages, single layered tablet would be economical, cost-effective and reproducible for large scale production in the industry. However, the results of present study demonstrated that the in vitro development of bilayered gastro retentive floating tablets with controlled drug release profile for LM is feasible.

Key words: Epilepsy, gastro retentive drug delivery system, hydroxy propyl methyl cellulose

INTRODUCTION

Epilepsy (sometimes referred to as a seizure disorder) is a common chronic neurological condition that is characterized by recurrent unprovoked epileptic seizures. Epileptic seizures result from abnormal, excessive or hyper synchronous neuronal activity in the brain.[1] About 50 million people world-wide have epilepsy and nearly 80% of epilepsy occurs in developing countries.[2] Epilepsy is usually controlled, but not cured, with medication.

Lamotrigine (LM) is an antiepileptic agent used as a monotherapy and as an adjunct with other antiepileptic agents for the treatment of partial seizures, primary and secondary generalized tonic — clonic seizures.[3] LM is a biopharmaceutical classification system (BCS) class II drug with pH dependent solubility (solubility in water is 0.17 mg/mL at 25°C while that in 0.1 M HCl 4.1 mg/mL at 25°C). LM is an amine containing compound with a good solubility in the acidic or the gastric media and its solubility decreases with increasing pH. Gastric retention of such a drug facilitates better absorption on account of its higher solubility at stomach’s acidic pH. It is rapidly and completely absorbed after oral administration with negligible first pass metabolism and requires multiple dosing (2-3 times daily) for maintaining the therapeutic effect throughout the day.[4,5]

Existing formulations of LM provide immediate release with t_max ranging from 1.4 h to 4.8 h and result into a release profile exhibiting cyclic peaks and troughs.[6] LM requires an extended release delivery system with differential control mechanisms in the gastric and intestinal regions to overcome its pH-dependent solubility. Glaxo Smithkline (GSK) manufactures Lamictal extended release (XR) tablets using conventional pharmaceutical excipients typical of those used for extended release tablets. Lamictal XR extended release tablets use the differential control release (DiffCORE) technology in combination with an enteric coat and a polymer system that swells and erodes to control the release rate of LM. Lamictal XR tablets are drilled on two sides

Access this article online

Quick Response Code:
Website: www.jpionline.org
DOI: 10.4103/2230-973X.119227
of the tablets and this modified release system is designed to deliver drug for 12-15 h.

Side-effects of the drug such as drug rash cosinophilia and systemic symptoms syndrome, Stevens-Johnson syndrome and toxic epidermal necrolysis caused by unregulated plasma concentrations of LM and the method of manufacturing using DiffCORE technology is highly laborious and expensive. In order to overcome the limitations of the available formulations, it was proposed to develop a less laborious, economic and an industrially applicable method for the delivery of LM with improved solubility and plasma concentrations within the therapeutic window over an extended period of time. Therefore, we consider gastro retentive mucoadhesive formulation of LM as one of the most attractive routes for the oral delivery of LM.

Gastro retentive drug delivery system is the technique in which the formulation is retained in the stomach for longer duration of time and hence the bioavailability of the drugs is improved preferentially absorbed from proximal gastrointestinal tract.[5] Gastro retentive dosage forms are of four main classes: (i) Floating systems, (ii) expandable systems, (iii) bio adhesive systems and (iv) high density systems.

Floating systems are of two types: Effervescent systems, depending on the generation of carbon dioxide gas upon contact with gastric fluids and non-effervescent systems. The latter systems can be further divided into four sub-types, including hydro dynamically balanced systems,[6] micro porous compartment systems,[7] Alginate beads[8] and hollow microspheres/microballoons.[9]

Floating drug delivery is of particular interest for drugs which:

• act locally in the stomach;
• are primarily absorbed in the stomach;
• are poorly soluble at an alkaline pH;
• have a narrow window of absorption and
• are unstable in the intestinal or colonic environment.[11]

In the present work bilayered effervescent floating tablets of LM were developed using excipients such as hydroxy propyl methyl cellulose (HPMC) grades (K100M, K15M, K4M, HPMC K100, HPMC E50 LV), hydroxypropyl cellulose (HPC)-M, Sodium bicarbonate, Ethyl cellulose E1415, polyvinyl pyrrolidone (PVP) K30, Xanthan gum, Eudragit RS100. Sodium bicarbonate on contact with gastric fluid releases CO2, which makes the tablet buoyant and improve the residence time at gastric pH.

MATERIALS AND METHODS

Materials
LM was a gift from RA Chem Pharma Ltd. (Hyderabad), HPMC-K100M Premium, HPMC-K15M Premium, HPMC-K4M Premium, HPMC-K100 Premium were purchased from Colorcon, HPMC-E50 LV (Lubrizol), Eudragit-RS100 were purchased from Corel Pharma Chem (Ahmadabad), Xanthan gum was purchased from Yarrow chem Products (Mumbai), Sodium bicarbonate and Magnesium stearate were purchased from SD fine chemicals (Mumbai), Talc from Accord labs (Hyderabad) and PVP K-30 from Burgoyne Burbidge’s & co (Mumbai).

Methods

Drug excipient compatibility

FTIR study
Fourier transform infrared (FTIR) study was performed to verify any physical or chemical interaction between the pure drug and the excipients. It was performed by potassium bromide (KBr) pellet method. The pure drug was triturated with KBr and pellet was prepared by setting the pressure to 100 kg/cm² for 2 min. The obtained pellet was analyzed in FTIR 8400 S, Shimadzu, Japan. KBr background was obtained initially before analysis of test samples. The same procedure was repeated for the analysis of drug-excipient physical mixture (drug and HPMC K100M) [Figure 1].

Differential scanning calorimetric study
Differential scanning calorimetry (DSC) study was performed to verify any physical or chemical interaction between the pure drug and the excipients.

Figure 1: Fourier transform infrared (FTIR) graph of pure drug and hydroxy propyl methyl cellulose (HPMC) K100M mixture
Preparation of tablets

Preparation of bilayered tablets

Bilayered tablets were prepared by direct compression procedure involving the following three consecutive steps:

- Step 1 (controlled release [CR] layer preparation): Accurately weighed quantities of drug and all other excipients were passed through #40 to get uniform sized particles and then they were mixed geometrically using a mortar and pestle for 10-15 min to ensure homogenous mixing. Magnesium stearate was added as a lubricant; talc was added as a glidant to the blended material and mixed. The amount of this CR polymer mixture sufficient for individual tablet weight was weighed separately and accurately [Table 1].

- Step 2 (floating layer preparation): Accurately weighed quantities of polymers, sodium bicarbonate and all other necessary excipients were mixed geometrically using a mortar and pestle for 10-15 min to ensure homogenous mixing. Magnesium stearate was added as a lubricant; talc was added as a glidant to the blended material and mixed. The amount of this floating polymer mixture sufficient for individual tablet weight was weighed separately and accurately [Tables 2 and 3].

- Step 3 (final tablet compression): Tablets were prepared by manually feeding each layer composition into the die and compressing the entire die content together in a 10 station punch machine using 11.1 mm concave shaped punch.

Irrespective of the composition of the CR drug layer and the floating layer, all the tablets formulated at each stage were prepared by the above mentioned procedure.

Preparation of single layered tablets

Single layered tablets were prepared from LFC4 formulation using direct compression method. Accurately weighed quantities of drug and all other excipients (used in bilayered tablet preparation) were passed through #40 to get uniform size particles and

### Table 1: Optimized formulations of controlled release drug layer and floating layer

| Ingredients (mg)       | LFC1 | LFC2 | LFC3 | LFC4 |
|------------------------|------|------|------|------|
| **Controlled release layer** |      |      |      |      |
| Lamotrigine            | 25   | 25   | 25   | 25   |
| HPMC K100M             | 25   | 50   | 100  | 150  |
| PVP K30                | 30   | 30   | 30   | 30   |
| **Floating layer**     |      |      |      |      |
| Sodium bi carbonate    | 40   | 40   | 40   | 40   |
| HPC-M                  | 100  | 100  | 100  | 100  |
| PVP K30                | 20   | 20   | 20   | 20   |
| **Total tablet weight in mg** | 280  | 305  | 355  | 405  |

All ingredients were lubricated with 0.3% (w/w) magnesium stearate, talc prior to compression, HPMC: Hydroxypropyl methyl cellulose, PVP: Polyvinyl pyrrolidine, HPC-M: Hydroxypropyl cellulose-M

### Table 2: Optimization of polymers for floating layer

| Batches | HPMC K15M | HPC-M | HPMC K100 | Sodium bicarbonate | PVP K30 |
|---------|-----------|-------|-----------|--------------------|---------|
| LF1     | 140       | 0     |          | 40                 | 20      |
| LF2     | 120       | 20    |          | 40                 | 20      |
| LF3     | 100       | 40    |          | 40                 | 20      |
| LF4     | 80        | 60    |          | 40                 | 20      |
| LF5     | 60        | 80    |          | 40                 | 20      |
| LF6     | 40        | 100   |          | 40                 | 20      |
| LF7     | 20        | 120   |          | 40                 | 20      |
| LF8     | 0         | 140   |          | 40                 | 20      |
| LF9     |          | 0     | 140      | 40                 | 20      |
| LF10    |          | 20    | 120      | 40                 | 20      |
| LF11    |          | 40    | 100      | 40                 | 20      |
| LF12    |          | 60    | 80       | 40                 | 20      |
| LF13    |          | 80    | 60       | 40                 | 20      |
| LF14    |          | 100   | 40       | 40                 | 20      |
| LF15    |          | 120   | 20       | 40                 | 20      |
| LF16    |          | 140   | 0        | 40                 | 20      |

All ingredients were lubricated with 0.3% (w/w) magnesium stearate, talc prior to compression, HPMC: Hydroxypropyl methyl cellulose, PVP: Polyvinyl pyrrolidine, HPC-M: Hydroxypropyl cellulose-M

### Table 3: Optimization of polymer quantity in floating layer

| Ingredients (mg)       | LP1 | LP2 | LP3 | LP4 | LP5 | LP6 | LP7 | LP8 |
|------------------------|-----|-----|-----|-----|-----|-----|-----|-----|
| **Controlled release layer** |     |     |     |     |     |     |     |     |
| HPMC K100              | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 |
| Lactose monohydrate    | 25  | 25  | 25  | 25  | 25  | 25  | 25  | 25  |
| PVP K30                | 30  | 30  | 30  | 30  | 30  | 30  | 30  | 30  |
| **Floating layer**     |     |     |     |     |     |     |     |     |
| Sodium bi carbonate    | 40  | 40  | 40  | 40  | 40  | 40  | 40  | 40  |
| HPMC K15M              | 40  | 40  | 40  | 40  | 40  | 40  | 40  | 40  |
| HPMC K4M               |     |     |     |     |     |     |     |     |
| HPMC K100              |     |     |     |     |     |     |     |     |
| HPMC ESOLV             |     |     |     |     |     |     |     |     |
| EC 1415                | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| HPC-M                  |     |     |     |     |     |     |     |     |
| PVP K30                | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  |
| **Total tablet weight in mg** | 405 | 405 | 405 | 405 | 405 | 405 | 405 | 405 |

All ingredients were lubricated with 0.3% (w/w) magnesium stearate, talc prior to compression, HPMC: Hydroxypropyl methyl cellulose, PVP: Polyvinyl pyrrolidine, HPC-M: Hydroxypropyl cellulose-M, EC: Ethyl cellulose
mixed geometrically using a mortar and pestle for 10-15 min to ensure homogenous mixing. Magnesium stearate was added as a lubricant and talc was added as a glidant to the blended material. Tablets were prepared by manually feeding the composition into the die and compressed using 11.1 mm concave shaped punch.

**Evaluation**

**Weight variation**
A total of 20 tablets were selected randomly from each batch and weighed using analytical balance. The average weight and standard deviation were calculated and not more than two tablets should deviate from the average weight by more than 7.5%.

**Hardness**
Tablet hardness was measured using a Monsanto hardness tester. The crushing strength of 10 tablets with known weight and thickness of each was recorded in kg/cm² and their average hardness with standard deviation was calculated.

**Friability**
A total of 20 tablets were selected from each batch and weighed. Each group of tablets was rotated at 25 rpm for 4 min (100 rotations) using Roche friabilator. The tablets were then dusted and re-weighed to determine the loss in weight. Friability was then calculated as percent weight loss from the original tablets. Conventional compressed tablets that lose < 0.5-1% of their weight were considered acceptable.

**Diametrical fracture**
It is a qualitative attribute concerned with the breaking of the tablet diametrically as opposed to de-laminating or capping and was tested by simple visual inspection.

**Thickness**
The thickness in millimetres (mm) was measured individually for 10 pre-weighed tablets using screw gauge and their average thickness with standard deviation were calculated.

**In vitro buoyancy studies**
In vitro buoyancy was determined by observing floating lag time (FLT) and floating time. The tablets were placed in a beaker containing 100 ml of 0.1N HCl. The time taken for the dosage form to emerge to the surface of the medium is called FLT or buoyancy lag time and the total duration of time up to which the dosage form remain buoyant is called total floating time (TFT).

**In vitro release studies**
The in vitro release studies of LM bilayered and single layered tablets were conducted using USP apparatus – II, fitted with paddle (50 rpm) at 37 ± 0.5°C using 900 ml of 0.1 NHCl as dissolution medium. Samples of 5 ml were withdrawn at 1, 2, 3, 4 and 5 up to 18 h at regular 1 h intervals and replaced with same volume of fresh medium. The samples were analyzed by ultraviolet spectrophotometry at 244 nm and the cumulative percentage release was calculated using the standard calibration curve. [11]

**Drug release kinetics**
Drug release kinetics was studied by plotting zero order, first order, Higuchi and Korsmeyer-Peppas equations. Regression coefficients ($r^2$) were calculated for all the formulations and the release component “n” was calculated from Korsmeyer-Peppas equation. Based on the “n” value release mechanism was characterized.

**Calculation of similarity and difference factors**
The dissolution results obtained from the single layered formulation was set as reference ($K$) and the results of the optimized bilayered formulation ($T_i$) was compared using difference factor ($f_j$) and similarity factor ($f_j^{[12,13]}$)

The similarity factor was calculated with the formula:

$$f_j = 50 \log \left\{ \left[ 1 + \frac{1}{n} \sum_{j=1}^{n} w_j |R_j - T_j|^2 \right]^{0.5} \times 100 \right\}$$

The difference factor was calculated with the formula:

$$f_i = \frac{\sum_{j=1}^{n} |R_j - T_j|}{\sum_{j=1}^{n} R_j} \times 100$$

**Accelerated stability studies for the optimized formulations**
Accelerated stability studies were conducted for the optimized formulations as per ICH guidelines. The studies were carried out at 40°C/75% RH for 3 months. The samples were withdrawn for every 1 month and evaluated for physical properties such as appearance, hardness, floating property, dissolution and assay.

**RESULTS AND DISCUSSION**

**Drug excipient compatibility**

**FTIR study**
The principal peaks of LM were observed at 1631.67 indicating the presence of N-H bending, 1583.45 for C=C of an aromatic ring, 1064.63 for C-N stretch of an aromatic amine and 962.41 cm⁻¹ for C-Cl of an aromatic halide. The characteristic peaks for drug and excipients mixture also appeared at 1631.67, 1583.45, 1064.63 and 962.41 cm⁻¹. No peaks were found at these wave numbers for excipients indicating no interaction between drug and the polymers therein.

**DSC**
Pure drug showed an endothermic peak at 250.9°C, exothermic peak at 283°C and pure HPMC K100M polymer showed an endothermic peak at 99.9°C. The drug-excipient mixture showed endothermic peaks at 103.7°C, 247.2°C, which indicates no interaction between drug and the polymers therein and the pure drug was not altered functionally.
Physical properties of the floating tablets
All the eight preliminary batches formulated as placebo tablets were evaluated for pre-compression flow property, angle of repose independently for both the layers and for in-process parameters such as hardness, thickness, friability, diametrical fracture. When hardness is in the range of 6-8 kg/cm² tablets did not float. So their hardness was adjusted to 4-5 kg/cm² for better FLT. Percentage friability ranging from 0.34% to 0.88% and thickness within 4.90-4.98 mm range were obtained. All the formulations LP1-LP8 passed the test for diametrical fracture, which reflects good adhesion between the two layers of the bilayered tablets and in turn their physical integrity. From the formulations, LP1-LP8 only LP2, LP6 were optimized for the further development of bilayered tablets, which consists of HPMC K15M, HPMC K100 respectively. Though LP1, LP3, LP5, LP7 batches containing ethyl cellulose showed good buoyancy effect but eroded within 6-8 h. Hence ethyl cellulose was replaced with HPC-M hydrophilic polymer which showed good FLT and total floating duration for 16 h and above in LP2 and LP6 formulations. They were further optimized for final formulation.

In vitro buoyancy studies
In vitro lag time measurement
Floating layer polymers HPMC K15M, HPMC K100 were used at different ratios in combination with HPC-M for the preparation of tablets and all the formulations showed a FLT <1 min.

Effect of sodium bicarbonate on floating lag
From the results, it was evident that sodium bicarbonate has significant effect on lag time. FLT decreased with the increase in sodium bicarbonate concentration.

TFT measurement
TFT for the optimized formulation was found to be >18 h.

In vitro release studies
When in vitro drug release studies of LM using different polymers were compared then the formulation LC4 with HPMC K100 showed maximum amount of drug release for prolonged period of time i.e., 97.2 ± 0.39 for 16 h. Then formulations LFC1-LFC4 were prepared using different proportions of HPMC K100. Among those formulations LFC4 was found to release maximum amount of drug for long period of time i.e., 99.14 ± 6.23% for 18 h. The dissolution profile of bilayered and single layer tablets were compared and were found to show similar results. Marketed Lamictal XR extended release tablet is designed to deliver the drug for 12-15 h by varying the aperture size and surface area [Figures 2-4].

Drug release kinetics
The final optimized formulation of bilayered tablets was found to follow zero order kinetics with fickian diffusion and single layer tablets followed higuchi release with fickian diffusion [Table 4 and Figure 1].

Table 4: Model dependent kinetic study for bilayered and single layered tablet

| Formulation       | Zero order release model parameters | First order release model parameter | Higuchi release model parameters | Korsmeyer-Peppas release model parameters | Release mechanism |
|-------------------|-------------------------------------|-------------------------------------|----------------------------------|------------------------------------------|-------------------|
|                   | r²                                  | r²                                  | r²                              | r²                                       | n                |
| Bilayered tablet  | 0.9901                              | 0.9879                              | 0.9311                          | 0.9836                                   | 0.4728           | Fickian diffusion |
| Single layered tablet | 0.9881                             | 0.926                               | 0.9896                          | 0.9859                                   | 0.4649           | Fickian diffusion |
Accelerated stability studies
The accelerated stability studies signify that the results comply with the specifications. The optimized formulation ensured physical integrity, reproducible floating property, promising drug release profiles and assay values after accelerated stability studies.

CONCLUSION
To conclude, an attempt has been made to achieve unidirectional, zero order release from a bilayered tablet which was successful, economical compared to expensive marketed LM (DIFFCORE™) tablets. The parameters such as FLT, TFT and controlled drug release were optimized in the study. The formulation was developed in 4 stages, the design of deformation resistant, pleasant appearing bilayered tablets, development of placebo bilayered tablets with maximum floating property, modulating controlled drug release profile and finally the comparison of release profiles between single layered and bilayered tablets.

Controlled drug release profile with zero order kinetics was obtained with LFC4 formulation. The formulations were stable under storage conditions and showed the potential for oral administration as bilayered gastro retentive floating tablets. Though bilayered tablet possess many advantages, single layered tablet would be economical, cost-effective and reproducible for large scale production in the industry. These results demonstrate that the in vitro development of bilayered gastro retentive floating tablets with controlled drug release profile for LM is feasible.

REFERENCES
1. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: Definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Epilepsia 2005;46:470-2.
2. Epilepsy. Fact sheets. World Health Organization; 2012. [Retrieved on 2013 Jan 24]. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/ [Last retrieved on Oct 12 2012].
3. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-400.
4. Goole J, Amighi K, Vanderbist F. Evaluation and floating enhancement of levodopa sustained release floating mini-tablets coated with insoluble acrylic polymer. Drug Dev Ind Pharm 2008;34:827-33.
5. Chavanpatil M, Jain P, Chaudhari S, Shear R, Vavia P. Development of sustained release gastroretentive drug delivery system for ofloxacin: In vitro and in vivo evaluation. Int J Pharm 2005;304:178-84.
6. Cheng CL, Chou CH, Hu OY. Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005;817:199-206.
7. Sharma N, Agarwal D, Gupta MK, Khinchi MP. A comprehensive review on floating drug delivery system. Int J Pharm Biomed Res 2011;2:2229-3701.
8. Harrigan RM. Drug delivery device for preventing contact of undissolved drug with the stomach lining. US Patent 1997;405:5178.
9. Talukder R, Fasshi R. Gastroretentive delivery systems: Hollow beads. Drug Dev Ind Pharm 2004;30:405-12.
10. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci 1992;81:135-40.
11. Tadros MI. Controlled-release effervescent floating matrix tablets of ciprofloxacin hydrochloride: Development, optimization and in vitro-in vivo evaluation in healthy human volunteers. Eur J Pharm Biopharm 2010;74:332-9.
12. Yuksel N, Kanik AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and independent methods. Int J Pharm 2000;209:57-6.
13. Maggio RM, Castellano PM, Kaufman TS. A new principal component analysis-based approach for testing “similarity” of drug dissolution profiles. Eur J Pharm Sci 2008;34:66-77.
14. Thomas OH, Adrian D, Jackie D, John D. A review of method used to compare dissolution profile data. Pharm Sci Technol Today 1998;1:214-33.
15. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.

How to cite this article: Lakshmi PK, Sridhar M, Shruthi B. Comparative evaluation of single and bilayered lamotrigine floating tablets. Int J Pharm Investig 2013;3:157-62.
Source of Support: Nil. Conflict of Interest: None.